Finding the right time for weaning off immunosuppression in solid organ transplant recipients

References

• Orlando G, Hematti P, Stratta RJ et al. Clinical operational tolerance after renal transplantation: current status and future challenges. Ann. Surg. (In Press) (2010).
   PubMedGoogle Scholar
• Baiocchi L, Angelico M, De Luca L et al. Cyclosporine A versus tacrolimus monotherapy. Comparison on bile lipids in the first three months after liver transplant in humans. Transpl. Int.19(5), 12–18 (2006).
   PubMedGoogle Scholar
• Lerut J, Mathys J, Verbaandert C et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomised, double-blind, placebo-controlled study. Ann. Surg.248(6), 956–967 (2008).
   PubMed Web of Science ®Google Scholar
• Sayegh M, Remuzzi G. Clinical update: immunosuppression minimisation. Lancet369(9574), 1676–1678 (2007).
   PubMedGoogle Scholar
• Hariharan S, Johnson CP, Bresnahan BA et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N. Engl. J. Med.342(9), 605–612 (2000).
   PubMed Web of Science ®Google Scholar
• Burlingham WJ, Jankowska-Gan E, VanBuskirk A et al. Loss of tolerance to a maternal kidney transplant is selective for HLA class II: evidence from trans-vivo DTH and alloantibody analysis. Hum. Immunol.61(12), 1395–1402 (2000).
   PubMedGoogle Scholar
• Karam VH, Gasquet I, Delvart V et al. Quality of life in adult survivors beyond 10 years after liver, kidney, and heart transplantation. Transplantation76(12), 1699–1704 (2003).
   PubMed Web of Science ®Google Scholar
• Galbraith CA, Hathaway D. Long-term effects of transplantation on quality of life. Transplantation77(9 Suppl.), S84–S87 (2004).
   PubMedGoogle Scholar
• Tisone G, Orlando G, Angelico M. Operational tolerance in clinical liver transplantation: emerging developments. Transpl. Immunol.17(12), 108–113 (2007).
   PubMed Web of Science ®Google Scholar
• Orlando G, Soker S, Wood KJ. Clinical operational tolerance after liver transplantation. J. Hepatol.50(6), 1247–1257 (2009).
   PubMed Web of Science ®Google Scholar
• Comerci GD, Williams TM, Kellie S. Immune tolerance after total lymphoid irradiation for heart transplantation: immunosuppressant-free survival for 8 years. J. Heart Lung Transpl.28(7), 743–745 (2009).
   PubMedGoogle Scholar
• Svendsen UG, Aggestrup S, Heilmann C et al. Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. Eur. Respir. J.8, 334–337 (1995).
   PubMedGoogle Scholar
• Starzl TE, Demetris AJ, Trucco M et al. Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology17(6), 1127–1152 (1993).
   PubMed Web of Science ®Google Scholar
• Reyes J, Zeevi A, Ramos H et al. Frequent achievement of a drug-free state after orthotopic liver transplantation. Transplant. Proc.25(6), 3315–3319 (1993).
   PubMed Web of Science ®Google Scholar
• Mazariegos GV, Ramos H, Shapiro R et al. Weaning of immunosuppression in long-term recipients of living related renal transplants: a preliminary study. Transplant. Proc.27(1), 207–209 (1995).
   PubMedGoogle Scholar
• Ramos HC, Reyes J, Abu-Elmagd K et al. Weaning of immunosuppression in long-term liver transplant recipients. Transplantation59(2), 212–217 (1995).
   PubMed Web of Science ®Google Scholar
• Mazariegos GV, Reyes J, Marino IR et al. Weaning of immunosuppression in liver transplant recipients. Transplantation63(2), 243–249 (1997).
   PubMed Web of Science ®Google Scholar
• Tzakis AG, Reyes J, Zeevi A et al. Early tolerance in pediatric liver allograft recipients. J. Pediatr. Surg.29(6), 754–756 (1994).
   PubMed Web of Science ®Google Scholar
• Mazariegos GV, Sindhi R, Thomson AW, Marcos A. Clinical tolerance following liver transplantation: long term results and future prospects. Transpl. Immunol.17(2), 114–119 (2007).
   PubMed Web of Science ®Google Scholar
• Thomson AW, Mazariegos GV, Reyes J et al. Monitoring the patient off immunosuppression. Conceptual framework for a proposed tolerance assay study in liver transplant recipients. Transplantation72(8 Suppl.), S13–S22 (2001).
   PubMed Web of Science ®Google Scholar
• Mazariegos GV, Zahorchak AF, Reyes J et al. Dendritic cell subset ratio in peripheral blood correlates with successful withdrawal of immunosuppression in liver transplant patients. Am. J. Transplant.3(6), 689–696 (2003).
   PubMed Web of Science ®Google Scholar
• Mazariegos GV, Zahorchak AF, Reyes J et al. Dendritic cell subset ratio in tolerant, weaning and non-tolerant liver recipients is not affected by extent of immunosuppression. Am. J. Transplant.5(2), 314–322 (2005).
   PubMed Web of Science ®Google Scholar
• Tokita D, Mazariegos GV, Zahorchak AF et al. High PD-L1/CD86 ratio on plasmacytoid dendritic cells correlates with elevated T-regulatory cells in liver transplant tolerance. Transplantation85(3), 369–377 (2008).
   PubMed Web of Science ®Google Scholar
• Devlin J, Doherty D, Thomson L et al. Defining the outcome of immunosuppression withdrawal after liver transplantation. Hepatology27(4), 926–933 (1998).
   PubMed Web of Science ®Google Scholar
• Girlanda R, Rela M, Williams R et al. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant. Proc.37(4), 1708–1709 (2005).
   PubMed Web of Science ®Google Scholar
• VanBuskirk AM, Burlingham WJ, Jankowska-Gan E et al. Human allograft acceptance is associated with immune regulation. J. Clin. Invest.106(1), 145–155 (2000).
   PubMed Web of Science ®Google Scholar
• Geissler F, Jankowska-Gan E, DeVito-Haynes LD et al. Human liver allograft acceptance and the ‘tolerance assay’: in vitro anti-donor T cell assays show hyporeactivity to donor cells, but unlike DTH, fail to detect linked suppression. Transplantation72(4), 571–580 (2001).
   PubMedGoogle Scholar
• Takatsuki M, Uemoto S, Inomata Y et al. Analysis of alloreactivity and intragraft cytokine profiles in living donor liver transplant recipients with graft acceptance. Transpl. Immunol.8(4), 279–286 (2001).
   PubMedGoogle Scholar
• Takatsuki M, Uemoto S, Inomata Y et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation72(3), 449–454 (2001).
   PubMed Web of Science ®Google Scholar
• Koshiba T, Li Y, Takemura M et al. Clinical, immunological, and pathological aspects of operational tolerance after pediatric living-donor liver transplantation. Transpl. Immunol.17(2), 94–97 (2007).
   PubMed Web of Science ®Google Scholar
• Li Y, Koshiba T, Yoshizawa A et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am. J. Transplant.4(12), 2118–2125 (2004).
   PubMed Web of Science ®Google Scholar
• Yoshizawa A, Ito A, Li Y et al. The roles of CD25+CD4+ regulatory T cells in operational tolerance after living donor liver transplantation. Transplant Proc.37(1), 37–39 (2005).
   PubMed Web of Science ®Google Scholar
• Pons JA, Yélamos J, Ramírez P et al. Endothelial cell chimerism does not influence allograft tolerance in liver transplant patients after withdrawal of immunosuppression. Transplantation75(7), 1045–1047 (2003).
   PubMedGoogle Scholar
• Tisone G, Orlando G, Cardillo A et al. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. J. Hepatol.44(4), 702–709 (2006).
   PubMed Web of Science ®Google Scholar
• Orlando G, Manzia T, Baiocchi L et al. The Tor Vergata weaning off immunosuppression trial in HCV liver transplant patients. The updated follow up at 78 months. Transpl. Immunol.20(1–2), 43–47 (2008).
   PubMed Web of Science ®Google Scholar
• Gras J, Wieërs G, Vaerman JL et al. Early immunological monitoring after pediatric liver transplantation: cytokine immune deviation and graft acceptance in 40 recipients. Liver Transpl.13(3), 426–433 (2007).
   PubMed Web of Science ®Google Scholar
• Hsu LW, Goto S, Nakano T et al. Immunosuppressive activity of serum taken from a liver transplant recipient after withdrawal of immunosuppressants. Transpl. Immunol.17(2), 137–146 (2007).
   PubMed Web of Science ®Google Scholar
• Alexander SI, Smith N, Hu M et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N. Engl. J. Med.358(4), 369–374 (2008).
   PubMed Web of Science ®Google Scholar
• Martínez-Llordella M, Lozano JJ, Puig-Pey I et al. Towards a diagnostic test of operational tolerance in liver transplantation employing transcriptional profiling. J. Clin. Invest.118(8), 2845–2857 (2008).
   PubMed Web of Science ®Google Scholar
• Martínez-Llordella M, Puig-Pey I, Orlando G et al. Multiparameter immune profiling of operational tolerance in liver transplantation. Am. J. Transpl.7(2), 309–319 (2007).
   PubMed Web of Science ®Google Scholar
• Pons JA, Ramírez P, Revilla-Nuin B et al. Immunosuppression withdrawal improves long-term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients. Clin. Transplant.23(3), 329–336 (2009).
   PubMedGoogle Scholar
• Pons JA, Revilla-Nuin B, Baroja-Mazo A et al. FoxP3 in peripheral blood is associated with operational tolerance in liver transplant patients during immunosuppression withdrawal. Transplantation86(10), 1370–1378 (2008).
   PubMed Web of Science ®Google Scholar
• Girnita A, Mazariegos GV, Castellaneta A et al. Liver transplant recipients weaned off immunosuppression lack circulating donor-specific antibodies. Hum. Immunol.71(3), 274–276 (2010).
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee SK, Lee HJ et al. Withdrawal of immunosuppression in pediatric liver transplant recipients in Korea. Yonsei Med. J.50(6), 784–788 (2009).
   PubMedGoogle Scholar
• Yoshitomi M, Koshiba T, Haga H et al. Requirement of protocol biopsy before and after complete cessation of immunosuppression after liver transplantation. Transplantation87(4), 606–614 (2009).
   PubMedGoogle Scholar
• Li Y, Zhao X, Cheng D et al. The presence of Foxp3 expressing T cells within grafts of tolerant human liver transplant recipients. Transplantation86(12), 1837–1843 (2008).
   PubMed Web of Science ®Google Scholar
• Assy N, Adams PC, Myers P et al. Randomized controlled trial of total immunosuppression withdrawal in liver transplant recipients: role of ursodeoxycholic acid. Transplantation83(12), 1571–1576 (2007).
   PubMedGoogle Scholar
• Assy N, Adams PC, Myers P et al. A randomised controlled trial of total immunosuppression withdrawal in stable liver transplant recipients. Gut56(2), 304–306 (2007).
   PubMedGoogle Scholar
• Matthes-Martin S, Peters C, Königsrainer A et al. Successful stem cell transplantation following orthotopic liver transplantation from the same haploidentical family donor in a girl with hemophagocytic lymphohistiocytosis. Blood96(12), 3997–3999 (2000).
   PubMed Web of Science ®Google Scholar
• Mellgren K, Fasth A, Saalman R et al.Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia. Ann. Hematol.84(11), 755–757 (2005).
   PubMedGoogle Scholar
• Donckier V, Troisi R, Toungouz M et al. Donor stem cell infusion after non-myeloablative conditioning for tolerance induction to HLA mismatched adult living-donor liver graft. Transpl. Immunol.13(2), 139–146 (2004).
   PubMed Web of Science ®Google Scholar
• Donckier V, Troisi R, Le Moine A et al. Early immunosuppression withdrawal after living donor liver transplantation and donor stem cell infusion. Liver Transpl.12(10), 1523–1528 (2006).
   PubMed Web of Science ®Google Scholar
• Craciun L, Stordeur P, Troisi R et al. A rapid test of alloreactivity based on interleukin-2 mRNA expression might identify liver transplant recipients with donor-specific hyporesponsiveness. Transplant Proc.39(8), 2665–2667 (2007).
   PubMedGoogle Scholar
• Tryphonopoulos P, Tzakis AG, Weppler D et al. The role of donor bone marrow infusions in withdrawal of immunosuppression in adult liver allotransplantation. Am. J. Transplant.5(3), 608–613 (2005).
   PubMed Web of Science ®Google Scholar
• Urban CH, Deutschmann A, Kerbl R et al. Organ tolerance following cadaveric liver transplantation for chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant.30(8), 535–537 (2002).
   PubMed Web of Science ®Google Scholar
• Kadry Z, Mullhaupt B, Renner EL et al. Living donor liver transplantation and tolerance: a potential strategy in cholangiocarcinoma. Transplantation76(6), 1003–1006 (2003).
   PubMed Web of Science ®Google Scholar
• Andreoni KA, Lin JI, Groben PA. Liver transplantation 27 years after bone marrow transplantation from the same living donor. N. Engl. J. Med.350(25), 2624–2625 (2004).
   PubMedGoogle Scholar
• Eason JD, Cohen AJ, Nair S et al. Tolerance: is it worth the risk? Transplantation79(9), 1157–1159 (2005).
   PubMed Web of Science ®Google Scholar
• Starzl TE, Murase N, Abu-Elmagd K et al. Tolerogenic immunosuppression for organ transplantation. Lancet361(9368), 1502–1510 (2003).
   PubMed Web of Science ®Google Scholar
• Starzl TE, Zinkernagel RM. Antigen localization and migration in immunity and tolerance. N. Engl. J. Med.339(26), 1905–1913 (1998).
   PubMed Web of Science ®Google Scholar
• Starzl TE, Zinkernagel RM. Transplantation tolerance from a historical perspective. Nat. Rev. Immunol.1(3), 233–239 (2001).
   PubMedGoogle Scholar
• Spitzer TR, Delmonico F, Tolkoff-Rubin N et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation68(4), 480–484 (1999).
   PubMed Web of Science ®Google Scholar
• Bühler LH, Spitzer TR, Sykes M et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation74(10), 1405–1409 (2002).
   PubMed Web of Science ®Google Scholar
• Fudaba Y, Spitzer TR, Shaffer J et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am. J. Transplant.6(9), 2121–2133 (2006).
   PubMed Web of Science ®Google Scholar
• Kawai T, Cosimi AB, Spitzer TR et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N. Engl. J. Med.358(4), 353–361 (2008).
   PubMed Web of Science ®Google Scholar
• Millan MT, Shizuru JA, Hoffmann P et al. Mixed chimerism and immunosuppressive drug withdrawal after HLA-mismatched kidney and hematopoietic progenitor transplantation. Transplantation73(9), 1386–1391 (2002).
   PubMed Web of Science ®Google Scholar
• Scandling JD, Busque S, Dejbakhsh-Jones S et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N. Engl. J. Med.358(4), 362–368 (2008).
   PubMed Web of Science ®Google Scholar
• Lerut J, Bonaccorsi-Riani E, Finet P, Gianello P. Minimization of steroids in liver transplantation. Transpl. Int.22(1), 2–19 (2009).
   PubMedGoogle Scholar
• Adam R, Lucidi V, Karam V. Liver transplantation in Europe: is there a room for improvement? J. Hepatol.42(1), 33–40 (2005).
   PubMed Web of Science ®Google Scholar
• Strober S, Lowsky RJ, Shizuru JA et al. Approaches to transplantation tolerance in humans. Transplantation77(6), 932–936 (2004).
   PubMedGoogle Scholar
• Farkas SA, Schnitzbauer AA, Kirchner G et al. Calcineurin inhibitor minimization protocols in liver transplantation. Transpl. Int.22(1), 49–60 (2009).
   PubMed Web of Science ®Google Scholar
• Neuberger JM, Mamelok RD, Neuhaus P et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the ‘ReSpECT’ study. Am. J. Transplant.9(2), 327–323 (2009).
   PubMed Web of Science ®Google Scholar
• Padbury RT, Gunson BK, Dousset B et al. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation55(4), 789–794 (1993).
   PubMedGoogle Scholar
• Padbury RT, Attard A, Mirza DF et al. Extended preservation of the liver with UW solution – is it justifiable? Transplantation57(10), 1490–1493 (1994).
   PubMedGoogle Scholar
• Moraes-Vieira PM, Silva HM, Takenaka MC et al. Differential monocyte STAT6 activation and CD4+CD25+Foxp3+ T cells in kidney operational tolerance transplanted individuals. Hum. Immunol.71(5), 442–450 (2010).
   PubMedGoogle Scholar
• Owens ML, Maxwell G, Goodnight J, Wolcott MW. Discontinuance of immunosuppression in renal transplant patients. Arch. Surg.110(12), 1450–1451 (1975).
   PubMedGoogle Scholar
• Zoller KM, Cho SI, Cohen JJ, Harrington JT. Cessation of immunosuppressive therapy after successful transplantation: a national survey. Kidney Int.18(1), 110–114 (1980).
   PubMedGoogle Scholar
• Najarian JS. Editorial comment. Arch. Surg.110(5), 1451 (1975).
   Google Scholar
• Hussey JL. Letter to: discontinuance of immunosuppression. Arch. Surg.111(5), 614 (1975).
   Google Scholar
• Uehling DT, Hussey JL, Weinstein AB et al. Cessation of immunosuppression after renal transplantation. Surgery79(3), 278–282 (1976).
   PubMedGoogle Scholar
• Van Buskirk AM, Burlingham WJ, Jankowska-Gan E et al. Human allograft acceptance is associated with immune regulation. J. Clin. Invest.106(1), 145–155 (2000).
   PubMedGoogle Scholar
• Xu Q, Lee J, Jankowska-Gan E et al. Human CD4+CD25low adaptive T regulatory cells suppress delayed-type hypersensitivity during transplant tolerance. J. Immunol.178(6), 3983–3995 (2007).
   PubMed Web of Science ®Google Scholar
• Fischer T, Schobel H, Barenbrock M. Specific immune tolerance during pregnancy after renal transplantation. Eur. J. Obst. Gyn.70(2), 217–219 (1996).
   Google Scholar
• Roussey-Kesler G, Giral M, Moreau A et al. Clinical operational tolerance after kidney transplantation. Am. J. Transpl.6(4), 736–746 (2006).
   PubMed Web of Science ®Google Scholar
• Ballet C, Roussey-Kesler G, Aubin JT et al. Humoral and cellular responses to influenza vaccination in human recipients naturally tolerant to a kidney allograft. Am. J. Transpl.6(11), 2796–2801 (2006).
   PubMed Web of Science ®Google Scholar
• Louis S, Braudeau C, Giral M et al. Contrasting CD25hiCD4+T cells/FOXP3 patterns in chronic rejection and operational drug-free tolerance. Transplantation81(3), 398–407 (2006).
   PubMed Web of Science ®Google Scholar
• Baeten D, Louis S, Braud C et al. Phenotypically and functionally distinct CD8+ lymphocyte populations in long-term drug-free tolerance and chronic rejection in human kidney graft recipients. J. Am. Soc. Nephrol.17(1), 294–304 (2006).
   PubMed Web of Science ®Google Scholar
• Brouard S, Dupont A, Giral M et al. Operationally tolerant and minimally immunosuppressed kidney recipients display strongly altered blood T-cell clonal regulation. Am. J. Transplant.5(2), 330–340 (2005).
   PubMed Web of Science ®Google Scholar
• Braudeau C, Ashton-Chess J, Giral M et al. Contrasted blood and intragraft toll-like receptor 4 mRNA profiles in operational tolerance versus chronic rejection in kidney transplant recipients. Transplantation86(1), 130–136 (2008).
   PubMed Web of Science ®Google Scholar
• Brouard S, Mansfield E, Braud C et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc. Natl Acad. Sci. USA104(39), 15448–15453 (2007).
   PubMed Web of Science ®Google Scholar
• Braud C, Baeten D, Giral M et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplant recipients: Part I. Blood gene expression statistical analysis. J. Cell Biochem.103(6), 1681–1692 (2008).
   PubMed Web of Science ®Google Scholar
• Sivozhelezov V, Braud C, Giacomelli L et al. Immunosuppressive drug-free operational immune tolerance in human kidney transplants recipients. Part II. Non-statistical gene microarray analysis. J. Cell Biochem.103(6), 1693–1706 (2008).
   PubMed Web of Science ®Google Scholar
• Newell KA, Asare A, Kirk AD et al. Identification of a B cell signature associated with renal transplant tolerance in humans. J. Clin. Invest.120(6), 1836–1847 (2010).
   PubMed Web of Science ®Google Scholar
• Sagoo P, Perucha E, Sawitzki B et al. Development of a cross-platform biomarker signature to detect renal transplant tolerance in humans. J. Clin. Invest.120(6), 1848–1861 (2010).
   PubMed Web of Science ®Google Scholar
• Christensen LL, Grunnet N, Rüdiger N et al. Indications of immunological tolerance in kidney transplantation. Tissue Antigens51(6), 637–644 (1998).
   PubMedGoogle Scholar
• Sayegh MH, Fine NA, Smith JL et al. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann. Int. Med.114(11), 954–955 (1991).
   PubMed Web of Science ®Google Scholar
• Helg C, Chapuis B, Bolle JF et al. Renal transplantation without immunosuppression in a host with tolerance induced by allogeneic bone marrow transplantation. Transplantation58(12), 1420–1422 (1994).
   PubMed Web of Science ®Google Scholar
• Jacobsen N, Taaning E, Ladefoged J et al. Tolerance to an HLA-B,DR disparate kidney allograft after bone-marrow transplantation from same donor. Lancet343(8900), 800 (1994).
   PubMed Web of Science ®Google Scholar
• Sorof JM, Koerper MA, Portale AA et al. Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation. Transplantation59(11), 1633–1635 (1995).
   PubMedGoogle Scholar
• Butcher JA, Hariharan S, Adams MB et al. Renal transplantation for end-stage renal disease following bone marrow transplantation: a report of six cases, with and without immunosuppression. Clin. Transplant.13(4), 330–335 (1999).
   PubMedGoogle Scholar
• Sellers MT, Deierhoi MH, Curtis JJ et al. Tolerance in renal transplantation after allogeneic bone marrow transplantation-6-year follow-up. Transplantation71(11), 1681–1683 (2001).
   PubMedGoogle Scholar
• Strober S, Dhillon M, Schubert M et al. Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N. Engl. J. Med.321(1), 28–33 (1989).
   PubMed Web of Science ®Google Scholar
• Strober S, Benike C, Krishnaswamy S et al. Clinical transplantation tolerance twelve years after prospective withdrawal of immunosuppressive drugs: studies of chimerism and anti-donor reactivity. Transplantation69(8), 1549–1554 (2000).
   PubMedGoogle Scholar
• Hutchinson JA, Brem-Exner BG, Riquelme P et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl. Int.21(8), 742–754 (2008).
   PubMedGoogle Scholar
• Hutchinson JA, Riquelme P, Brem-Exner BG et al. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl. Int.21(8), 728–741 (2008).
   PubMed Web of Science ®Google Scholar
• Danger R, Giral M, Soulillou JP, Brouard S. Rationale and criteria of eligibility for calcineurin inhibitor interruption following kidney transplantation. Curr. Opin. Organ Transplant.13(6), 609–613 (2008).
   PubMedGoogle Scholar
• Haller M, Oberbauer R. Calcineurin inhibitor minimization, withdrawal and avoidance procotols after kidney transplantation. Transpl. Int.22(6), 69–77 (2009).
   PubMedGoogle Scholar
• Ekberg H, Grinyó J, Nashan B et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am. J. Transplant.7(3), 560–570 (2007).
   PubMed Web of Science ®Google Scholar
• Anjum S, Andany MA, McClean JC et al. Defining the risk of elective cyclosporine withdrawal in stable kidney transplant recipients. Am. J. Transplant.2(2), 179–185 (2002).
   PubMedGoogle Scholar
• Abramowicz D, Del Carmen Rial M, Vitko S et al. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J. Am. Soc. Nephrol.16(7), 2234–2240 (2005).
   PubMed Web of Science ®Google Scholar
• Hazzan M, Labalette M, Copin MC et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J. Am. Soc. Nephrol.16(8), 2509–2516 (2005).
   PubMed Web of Science ®Google Scholar
• Hazzan M, Buob D, Labalette M et al. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation82(5), 657–662 (2006).
   PubMed Web of Science ®Google Scholar
• Pascual J, Bloom D, Torrealba J et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am. J. Transplant.8(7), 1529–1536 (2008).
   PubMed Web of Science ®Google Scholar
• Matas AJ. Minimization of steroids in kidney transplantation. Transpl. Int.22(1), 38–48 (2009).
   PubMed Web of Science ®Google Scholar
• Li L, Chang A, Naesens M et al. Steroid-free immunosuppression since 1999: 129 pediatric renal transplants with sustained graft and patient benefits. Am. J. Transplant.9(6), 1362–1372 (2009).
   PubMed Web of Science ®Google Scholar